Program:
Overview of significant clinical aspects presented during the meeting, including:

• 2025 European LeukemiaNet (ELN) recommendations for the management of CML (Jane Apperley on behalf of the ELN Consensus Panel) [01:15]
• Asciminib shows superior tolerability versus nilotinib in newly diagnosed CML in chronic-phase: Primary results of the Phase 3b ASC4START Trial (Andreas Hochhaus) [10:49]
• CML treatment discontinuation after a two-step dose reduction. First results of the phase 2 study HALF (Jiří Mayer) [13:04]
• ENABLE: A phase 1a/1b study of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with previously treated CML (Andreas Hochhaus) 15:19]
• Characterization and efficacy of TERN-701 in pre-clinical models of CML (Timothy Hughes) [18:00]
• Q&A Session (covering biological and clinical questions) [20:42]

If you have any questions or comments to the speaker, please email info@cml-foundation.org.